Description
Key facts
Cell type:SW480,
Species or organism:Human,
Tissue:Colon,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 1 bp deletion Frameshift: 100%,
Disease:Adenocarcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-BACE2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
BACE2 also known as beta-site APP-cleaving enzyme 2 is an aspartic acid protease. It has a molecular mass of roughly 70 kDa. This enzyme cleaves amyloid precursor protein (APP) at the beta-secretase site. BACE2 is mainly expressed in the brain but also found in other tissues like the pancreas. It shares similarity with BACE1 another protease involved in APP processing.
Biological function summary
BACE2 acts on substrates to regulate amyloidogenic processing of APP. It belongs to the peptidase A1 Family. Unlike its counterpart BACE1 which promotes amyloid-beta peptide production BACE2 has been suggested to reduce amyloid-beta formation by different substrate cleavage. Though not part of a stable complex BACE2 influences pathways related to protein processing.
Pathways
One should note that BACE2 is involved in the amyloidogenic pathway. This pathway processes APP and affects amyloid-beta levels important in neurological conditions. BACE2 acts with proteins like APP and might modulate the effects seen due to BACE1 activity. Despite overlapping functions BACE2 and BACE1 have distinct roles in this pathway impacting amyloid levels differently.
People look at BACE2 because of its connection to Alzheimer's disease and Down syndrome. BACE2 might act as a protective factor against Alzheimer's by limiting amyloid-beta accumulation. Down syndrome characterized by trisomy 21 involves heightened BACE2 expression which may modify neurodevelopment. In Alzheimer's research BACE1 has been the focus due to its role in disease progression but BACE2's contrasting effects offer a potential therapeutic angle.
